Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and related neurological conditions. Its lead program, buntanetap, is being advanced for Alzheimer’s disease and Parkinson’s disease, with additional patent claims covering acute brain and nerve injuries, neuropsychiatric indications, infections of the brain, and other disease areas. The company was founded in 2008 and is headquartered in Malvern, Pennsylvania. Annovis has not commercialized any product and currently operates as a single operating segment centered on research, development, and clinical execution.
| % | |
|---|---|
| Lead therapeutic candidate development | 70% Development of buntanetap as a treatment for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. |
| Pipeline expansion and new indications | 15% Research and patenting around additional uses for buntanetap in brain injury, neuropsychiatric, infectious, and oncology-related settings. |
| Preclinical and follow-on assets | 10% Development work on Posiphen, Posiphen Form B, and ANVS402 as related proprietary compounds. |
| Intellectual property and licensing value | 5% Patent filings and composition-of-matter protection intended to extend exclusivity and support future partnering. |
Annovis does not currently sell commercial products, so it has no traditional paying customer base today...
Patients with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders who would use buntanetap or related therapies if approved.
Neurologists, memory clinics, movement-disorder specialists, and hospitals that would diagnose, prescribe, and monitor treatment.
Commercial insurers, Medicare/Medicaid, and other payors that would determine coverage, medical necessity, and reimbursement terms.
CROs, CMOs, investigators, and consultants that support development, manufacturing, and regulatory submissions.
Pharmaceutical partners that could help commercialize approved products in exchange for rights or economics.
Annovis is headquartered in Malvern, Pennsylvania, and substantially all of its assets are located in the United States...
Annovis’ strategy is centered on advancing buntanetap through late-stage clinical development and regulatory review in...
Clinical readouts and regulatory progress are the main value drivers for a company with no commercial revenue.
The company states it does not have sufficient capital to fund operations for the next 12 months and needs additional funding to continue development.
Patent protection is essential for future exclusivity, partnering leverage, and eventual commercial value.
The company has no internal sales, marketing, or distribution capabilities and will need a route to market if approval is achieved.
Annovis faces the classic risks of a clinical-stage biotechnology company: trial failure, regulatory delay, and the...
The company states it does not have sufficient capital to fund operations for the next 12 months and will need substantial additional financing.
Buntanetap is still in development, and negative trial results would materially impair the company’s prospects.
Even if approved, third-party payors may not view the therapy as medically necessary or cost-effective.
The company relies on third-party manufacturers and has limited control over cGMP compliance and supply continuity.
Competitors have greater resources, broader pipelines, and more established commercialization capabilities.
AVXL · Biological Products, (No Diagnostic Substances)
PASG · Biological Products, (No Diagnostic Substances)
BIVI · Pharmaceutical Preparations
PMN · Pharmaceutical Preparations
KLRS · Biological Products, (No Diagnostic Substances)
NVCT · Pharmaceutical Preparations
: 11/08/2026